ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients

K. Nunez, T. Sandow, P. Thevenot, A. Cohen

Ochsner Health System, New Orleans, LA

Meeting: 2020 American Transplant Congress

Abstract number: 253

Keywords: Hepatocellular carcinoma, Liver, Liver transplantation, N/A

Session Information

Date: Saturday, May 30, 2020

Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies II

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

Related Abstracts
  • Predictive Value of mRECIST in HCC Response to the Neoadjuvant Locoregional Therapies and Prognosis Affected by the Peak AFP Level before Liver Transplantation
  • Evaluation of Liver Function and Biomarkers Predicts Tumor Progression in Treatment-Naïve Hepatocellular Carinoma Patients

*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC patients undergoing de novo LRT and monitored intention-to-treat (ITT) survival. We also prospectively monitored a subset of early-stage HCC patients to determine whether additional HCC biomarkers would aid in predicting ITT survival compared to AFP alone.

*Methods: All studies were IRB-approved at our institution. HCC patients undergoing de novo DEB-TACE from Aug 2015 – May 2019 were reviewed. Blood was collected from a subset of these patients (n=51) immediately prior to LRT. Plasma was used to measure HCC biomarkers (AFP, des-γ-carboxy prothrombin (DCP), and Lens culinaris agglutinin-reactive α-fetoprotein (AFP-L3)) in samples with the μTASWako i30 autoanalyzer. ITT endpoint included patients that received liver transplantation or dropout due to tumor progression.

*Results: 160 treatment-naïve HCC patients were analyzed with 71% male and 65% Hepatitis C. Milan Criteria and AFP elevation alone was not predicitive ITT survival, however patients with AFP > 100ng/ml had significantly lower ITT survival. Univariate analysis revealed patients with tumor progression had larger lesions (P<0.0001), cumulative lesion size (P<0.0001), and higher HCC biomarkers AFP (P=0.39), AFP-L3 (P=0.002), and DCP (P=0.005). ITT survival was significantly lower in patients presenting with elevated single biomarkers [AFP >100 (P<0.0001), AFP-L3 (P<0.0001), and DCP (P<0.0001)], primary lesion >3cm (P<0.0001), and cumulative lesion size >3cm (P<0.001). Analysis of patients stratified by HCC biomarkers revealed patients presenting with AFP elevation and an additional biomarker had worse ITT survival and were at greater risk of waitlist dropout.

*Conclusions: AFP alone can identity patients at risk of waitlist dropout with higher risk of recurrence post transplant. However, the addition of AFP-L3 and DCP biomarkers can identify a patient population prior to LRT intervention at risk of tumor progression from the waitlist.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Nunez K, Sandow T, Thevenot P, Cohen A. Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/biomarkers-afp-in-combination-with-afp-l3-and-dcp-predicts-tumor-progression-in-treatment-native-hcc-patients/. Accessed February 28, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.